10-Q: Lantern Pharma Faces Going Concern Amid Cash Burn

Lantern Pharma Inc. reported a reduced net loss in Q2 2025 but faces substantial doubt about its ability to continue as a going concern due to significant cash burn and declining liquidity.

Summary

• Lantern Pharma Inc. reported a net loss of $8.87 million for the six months ended June 30, 2025, an improvement from $10.40 million in the same period of 2024.
• Total operating expenses decreased by 15.4% to $9.43 million for the six months ended June 30, 2025, primarily driven by a 22% reduction in research and development (R&D) expenses.
• R&D expenses for the six months ended June 30, 2025, included $2.17 million for LP-300, $2.63 million for LP-184, $0.73 million for LP-284, $0.06 million for LP-100, $0.01 million for the ADC Program, and $0.52 million for the RADR Platform.
• General and administrative (G&A) expenses increased by 3% to $3.09 million for the six months ended June 30, 2025.
• Cash and cash equivalents, combined with marketable securities, totaled $15.90 million as of June 30, 2025, down from $24.01 million at December 31, 2024.
• The company used $8.31 million in cash from operating activities during the first six months of 2025, a slight increase from $8.26 million in the prior year period.
• Lantern Pharma believes its current liquidity will fund operations into June 2026 but requires substantial additional funding in the near future.
• An At-The-Market (ATM) Sales Agreement was entered into in July 2025, allowing the sale of up to $15.53 million in common stock; $80,000 has been raised through August 12, 2025.
• The company is advancing three clinical-stage oncology drug candidates (LP-300, LP-184, LP-284) and an Antibody Drug Conjugate (ADC) program, leveraging its AI platform, RADR.

Sentiment

Score: 3

Explanation: While the net loss decreased and R&D efforts continue, the significant decline in liquidity and the explicit 'going concern' warning are major red flags. The immediate need for substantial additional funding creates high financial uncertainty, overshadowing operational progress.

Positives

• Net loss decreased to $8.87 million for the six months ended June 30, 2025, compared to $10.40 million for the same period in 2024, indicating improved financial results.
• Research and development expenses decreased by 22% to $6.33 million for the six months ended June 30, 2025, suggesting more efficient use of R&D capital or a shift in development phase.
• The company continues to advance three clinical-stage oncology drug candidates (LP-300, LP-184, LP-284) and an Antibody Drug Conjugate (ADC) program, demonstrating ongoing pipeline progression.
• The proprietary RADR AI platform, with over 200 billion data points, is being leveraged to streamline drug development and identify patient populations, potentially de-risking future trials.

Negatives

• The company's cash, cash equivalents, and marketable securities significantly decreased to $15.90 million as of June 30, 2025, from $24.01 million at December 31, 2024, indicating a high cash burn rate.
• Working capital declined substantially to $12.32 million as of June 30, 2025, from $20.92 million at December 31, 2024.
• Net cash used in operating activities slightly increased to $8.31 million for the six months ended June 30, 2025, compared to $8.26 million in the prior year, reflecting continued operational cash outflow.
• The company explicitly states that factors raise 'substantial doubt about the Company's ability to continue as a going concern' without obtaining substantial additional funding.
• Interest income decreased by 39% for the three months ended June 30, 2025, and by 32% for the six months ended June 30, 2025, reflecting lower cash balances or interest rates on investments.
• Other income, net, decreased for both the three and six-month periods ended June 30, 2025, primarily due to decreases in dividend income.

Risks

• Ability to secure sufficient funding and alternative sources of funding to support existing and proposed preclinical studies and clinical trials.
• Uncertainties regarding the initiation, timing, progress, and results of preclinical studies or clinical trials for any drug candidates.
• Inability to fund operating expenses and capital expenditure requirements with existing cash, cash equivalents, and marketable securities beyond June 2026.
• Substantial additional funding is required in the near future, and failure to raise capital could force delays, reductions, or elimination of drug development programs or commercialization efforts.
• The company's ability to continue as a going concern is highly contingent on raising additional capital for ongoing research and development and clinical trials.
• Market value fluctuations of marketable securities due to changes in interest rates, market conditions, and credit risk.
• Cash balances held at banking institutions may from time to time exceed federally insured limits.
• Reliance on foreign third-party manufacturers and service providers, subject to U.S. and international trade policies and potential tariffs.
• Geopolitical risks, including in Taiwan, where clinical testing of LP-300 is being pursued.
• Competition, manufacturing capability, and commercial viability could impact the probability of success for each drug candidate.
• Future capital raises through equity sales could materially dilute existing stockholders' ownership interests.
• Debt financing, if available, could result in increased fixed payment obligations and restrictive covenants.
• Inability to raise capital on attractive terms could force the company to seek collaborators at an earlier stage or license rights on unfavorable terms.
• Inflation could increase labor and clinical trial costs, negatively impacting future results of operations.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it develops its pipeline, conducts additional preclinical studies and clinical trials, and potentially seeks regulatory clearance and prepares for commercialization. It anticipates substantial expenditures for research and service provider agreements. The company believes its existing cash, cash equivalents, and marketable securities will fund operations into June 2026 but will need substantial additional funding in the near future. It plans to pursue periodic capital raises, including potential sales under the ATM Sales Agreement, and may explore commercial credit facilities. The company does not expect to generate revenue, other than possible license and grant revenue, until successful development and regulatory approval of its therapeutic candidates.

Management Comments

• "We believe that our existing cash, cash equivalents, and marketable securities as of June 30, 2025, and our anticipated expenditures and capital commitments, will enable us to fund our operating expenses and capital expenditure requirements at least into June 2026."
• "We will need substantial additional funding in the near future, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development programs or commercialization efforts."
• "Our ability to continue as a going concern is highly contingent on the ability to raise additional capital for ongoing research and development and clinical trials as we expect to continue incurring losses for the foreseeable future."
• "These factors raise substantial doubt about our ability to continue as a going concern in the absence of obtaining substantial additional funding."
• "While we plan to pursue periodic capital raises, including potential sales under the ATM Sales Agreement, no assurance can be given that sufficient funding will be available when needed to allow us to continue as a going concern."

Industry Context

Lantern Pharma operates in the highly competitive and rapidly evolving oncology drug discovery and development sector. The company distinguishes itself by leveraging artificial intelligence (AI) and machine learning through its proprietary RADR platform to identify drug candidates, predict patient response, and streamline the drug development process. This data-driven approach aligns with a broader industry trend towards precision oncology and de-risking development through computational biology. The company's strategy of both developing new, biomarker-guided drug candidates and 'rescuing' historical drug candidates that failed due to lack of patient stratification is emblematic of a new era in drug development focused on data-intensive approaches.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry comparison.
• For LP-100, the median overall survival (OS) of approximately 12.5 months in a previous Phase 2 trial for metastatic castration-resistant prostate cancer (mCRPC) was noted as an 'improvement over other similar fourth-line treatment regimens for mCRPC,' but no specific comparable regimens or companies were detailed.

Corporate Governance

Related Party Transactions

• The company has a Collaboration Agreement with Actuate Therapeutics, Inc., a clinical-stage private biopharmaceutical company.
• Certain affiliates of Bios Partners, who beneficially own greater than 10% of Lantern Pharma's common stock, also hold substantial beneficial ownership interests in Actuate Therapeutics.
• As part of the collaboration, Lantern Pharma received 25,000 restricted shares of Actuate stock in May 2021, which converted to 13,889 shares of common stock after Actuate's August 2024 IPO and reverse stock split.
• No revenues have been recognized under the Collaboration Agreement through June 30, 2025.

Stakeholder Impact

• Shareholders face potential dilution from the ongoing At-The-Market (ATM) equity offering and significant risk to investment value due to the 'going concern' warning if additional funding is not secured.
• Employees are impacted by the company's continued research and development activities, with potential for future hiring to support expanded operations.
• Future cancer patients are the ultimate beneficiaries if the company's drug candidates successfully complete development and obtain regulatory approval.
• Creditors face increased risk given the company's explicit 'going concern' warning and reliance on future capital raises to sustain operations.

Next Steps

• Continue development, including preclinical studies and clinical trials, of existing drug candidates (LP-300, LP-184, LP-284, ADC program, LP-100).
• Initiate preclinical studies and clinical trials for any additional indications for current and future drug candidates.
• Build the portfolio of drug candidates through acquisition or in-license of additional candidates or technologies.
• Continue to develop, maintain, expand, and protect the intellectual property portfolio.
• Pursue regulatory approvals for drug candidates that successfully complete clinical trials.
• Establish a sales, marketing, distribution, and other commercial infrastructure for any approved drug candidates.
• Hire additional clinical, regulatory, scientific, and accounting personnel.
• Incur additional legal, accounting, and other expenses associated with operating as a public company.
• Continue to develop, maintain, and expand the RADR AI platform.
• Pursue periodic capital raises, including sales under the ATM Sales Agreement.
• Apply for grant funding to support capital needs.
• Explore the possibility of entering into commercial credit facilities.
• Assess the potential impact of the One Big Beautiful Bill Act (H.R. 1) on gross tax assets and liabilities in future periods.
• Assess the effect of ASU 2023-09 and ASU 2024-03 on financial statement disclosures.

Key Dates

Recommendation

The explicit 'substantial doubt about the Company's ability to continue as a going concern' is a paramount risk for any investment. Despite a reduced net loss, the significant decline in cash and marketable securities, coupled with an increased cash burn from operations, highlights a deteriorating liquidity position. The ongoing ATM offering, while a necessary step, underscores the immediate and critical need for capital. For a seasoned investor, the high financial uncertainty and the fundamental going concern issue outweigh the operational progress in clinical programs, making the stock a high-risk proposition with a strong potential for further downside.

Keywords

Oncology, Biotechnology, Artificial Intelligence, Drug Development, Clinical Trials, Cancer Therapies, SEC Filing, 10-Q, Financial Report, Liquidity, Going Concern, LP-300, LP-184, LP-284, ADC Program, RADR Platform